(Q35917234)

11 August 2017

1 reference

title

Atazanavir: improving the HIV protease inhibitor class (English)

1 reference

11 August 2017

1 reference

Stephen Becker

1

1 reference

11 August 2017

publication date

1 October 2003

1 reference

Expert Review of Anti-infective Therapy

11 August 2017

published in

1 reference

11 August 2017

volume

1

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

403-413

1 reference

Managing resistance to anti-HIV drugs: an important consideration for effective disease management.

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.403

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.403

Viral dynamics in human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.403

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.403

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.403

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.403

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.403

Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.403

Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.403

Effect of Combination Therapy Including Protease Inhibitors on Mortality among Children and Adolescents Infected with HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.403

21 January 2018

Identifiers

DOI

10.1586/14787210.1.3.403

1 reference

11 August 2017

1 reference